|
VCEL | Vericel Corp |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.18 |
| Leverage | 28.99% |
| Market Cap | $ 1.8B |
| PE | 141.01 |
| Dividend Yield | 0.00% |
| Profit | $ 12.8m |
| Margin | 5.02% |
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.